1. Home
  2. JBGS vs NVAX Comparison

JBGS vs NVAX Comparison

Compare JBGS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBG SMITH Properties

JBGS

JBG SMITH Properties

HOLD

Current Price

$17.63

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.03

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBGS
NVAX
Founded
2016
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
JBGS
NVAX
Price
$17.63
$8.03
Analyst Decision
Sell
Hold
Analyst Count
1
8
Target Price
$18.00
$9.75
AVG Volume (30 Days)
541.3K
4.2M
Earning Date
02-17-2026
02-26-2026
Dividend Yield
3.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.07
Revenue
$501,226,000.00
$1,064,651,000.00
Revenue This Year
N/A
$58.91
Revenue Next Year
$1.79
N/A
P/E Ratio
N/A
$3.87
Revenue Growth
N/A
20.27
52 Week Low
$13.28
$5.01
52 Week High
$24.30
$10.65

Technical Indicators

Market Signals
Indicator
JBGS
NVAX
Relative Strength Index (RSI) 56.29 60.99
Support Level $16.84 $7.15
Resistance Level $17.63 $8.81
Average True Range (ATR) 0.41 0.41
MACD 0.12 0.11
Stochastic Oscillator 98.21 64.99

Price Performance

Historical Comparison
JBGS
NVAX

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: